US FDA calls for tougher warnings on TNF-alpha drugs on 240 cases of histoplasmosis
US regulators are calling for stronger label warnings on tumour necrosis factor-alpha drugs as they increase the risk of fungal infections.
The Food and Drug Administration says that the manufacturers of these blockbuster products, commonly used to treat rheumatoid arthritis and other serious illnesses, must strengthen the existing warnings in their prescribing information and medication guides, adding cautions on the risk of developing opportunistic fungal infections.
Read the full article here